29.38
+3.12%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Amphastar Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Amphastar Pharmaceuticals is based in Rancho Cucamonga, California. Its shares trade on Nasdaq under the ticker AMPH. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $719.9m and net income of $98.1m. At that date it held total assets of $1.63bn and shareholders' equity of $788.8m.
We are a biopharmaceutical company focusing on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredient, or API products. We currently manufacture and sell over 25 prescription pharmaceutical products, and an over-the-counter product, Primatene MIST®.
Our largest products by net revenues currently include BAQSIMI® glucagon nasal powder, or BAQSIMI®, Primatene MIST®, glucagon, epinephrine, and lidocaine.
In June 2023, we completed our acquisition of BAQSIMI®, the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes, and it is currently available in the United States and 26 international markets.
In May 2024, the FDA approved our albuterol sulfate inhalation aerosol, which we launched in August 2024.
In August 2025, the FDA approved our iron sucrose injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, which we launched in the August 2025.
In December 2025, the FDA approved our teriparatide injection, USP 560mcg/2.24mLsingle-patient-use prefilled pen, which we launched in the December 2025.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jun 2014
- Employees
- 1,976
- Website
- amphastar.com ↗
- Head office
- 11570 SIXTH STREET, RANCHO CUCAMONGA, CA, 91730
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Ziping LuoChairman of the Board, Chief Operating Officer, Chief Scientist, since 1996$3.8m
- Dr. Yongfeng ZhangPresident, Chief Executive Officer, Chief Scientific Officer, Director, since 1996$7.7m
- Mr. William PetersChief Financial Officer, Executive Vice President - Finance, Treasurer, President of International Medication Systems Limited, Director, since 2014$2.9m
- Mr. Jacob LiawatidewiExecutive Vice President of Sales and Marketing, Corporate Administration Center, President of Amphastar France Pharmaceuticals, S.A.S, Company Secretary, Director, since 2014$1.8m
- Mr. Rong ZhouSenior Executive Vice President of Production Center, Executive Vice President of Scientific Affairs, President of Amphastar Nanjing Pharmaceuticals, Co., Ltd.$2.1m
- Mr. Richard PrinsLead Independent Director$375,121
- Mr. David GaughDirector
- Ms. Gayle DeflinIndependent Director$340,003
- Ms. Diane GerstIndependent Director, since 2014$327,644
- Dr. Howard LeeIndependent Director$333,290
- Mr. Floyd PetersenIndependent Director$325,003
- Dr. Michael ZasloffIndependent Director$331,003
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 37
- Environment
- 4
- Social
- 45
- Governance
- 61
- Carbon reduction policy
- No
- Human rights policy
- Yes
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.